Abliva: Potentially faster to market

Research Note



Redeye maintains its fair value of Abliva at SEK 1.4 per share. Optimism around its main asset, KL1333, has increased, but there are still many unknowns concerning clinical outcomes and financing.


Gergana Almquist

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.